Fig. 1 · Structure

Documents & Downloads

Varenicline

Cat. No. A10966 CAS 249296-44-4

nAChR partial agonist

Varenicline is a nicotinic receptor partial agonist.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Varenicline Research Summary

This section summarizes 4 in vivo studies of Varenicline from 3 published references. In vivo models include male Wistar rats.

Varenicline In Vivo Studies

In male Sprague–Dawley rats, intraperitoneal Varenicline pretreatment reduced the increase associated with nicotine omission in Cluster B but had no significant effect in Cluster A, compared with omission without pretreatment. In male Wistar rats, intraperitoneal Varenicline affected active nose pokes, with post hoc analyses showing significantly reduced nicotine self-administration compared with vehicle. In male Wistar rats chronically drinking ethanol, Varenicline microinfusion into the NAc core-shell border did not affect ethanol or water intake compared with vehicle. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Varenicline and nicotine omission in Cluster B rats

Animal study · Male Sprague–Dawley rats; n = 26 Cluster B [1]

Male Sprague–Dawley rats in Cluster B received Varenicline at 1 mg/kg free base by intraperitoneal injection. Varenicline pretreatment reduced the increase associated with nicotine omission compared with nicotine omission without Varenicline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Global effect of nicotine omissionReported result Varenicline reduced this increase (NicOm+Var) in Cluster B[1]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
30 min before the session began; session 23
Vehicle
sterile 0.9% physiological saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Varenicline 1 mg/kg free basenicotine omission without (NicOm)Varenicline reduced this increase (NicOm+Var) in Cluster B[1]
Varenicline 1 mg/kg free base
Model: Male Sprague–Dawley rats; n = 26 Cluster B
Methods and source locations

Compound reported in the paper: Varenicline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Nicotine intravenous self-administration (S17); Materials and methods > Nicotine intravenous self-administration > Self-administration standard protocol (S22); Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 1 legend (S157); Fig. 4 legend (S170)

Global effect of nicotine omission: Global effect of nicotine omission; comparator: nicotine omission without (NicOm) — Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 4 legend (S170)

Varenicline 1 mg/kg free base · Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155)

Varenicline and nicotine self-administration in Wistar rats

Animal study · Male Wistar rats [2]

Male Wistar rats received intraperitoneal Varenicline before testing. Compared with vehicle, 1.5 mg/kg and 2.5 mg/kg significantly reduced nicotine self-administration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total number of active nose pokesReported result Varenicline treatment had an overall main effect on the total number of active nose pokes (F(3,27) = 36.04, p < 0.001), and further post hoc analyses revealed that 1.5 mg/kg and 2.5 mg/kg varenicline significantly reduced nicotine self-administration compared to vehicle[2]

Conditions shared by the study groups

Route
intraperitoneally
Treatment course
30 min before testing
Vehicle
1% methylcellulose–5% mannitol solution
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Varenicline 0.5, 1.5 and 2.5 mg/kgvehicleVarenicline treatment had an overall main effect on the total number of active nose pokes (F(3,27) = 36.04, p < 0.001), and further post hoc analyses revealed that 1.5 mg/kg and 2.5 mg/kg varenicline significantly reduced nicotine self-administration compared to vehicle[2]
Varenicline 0.5, 1.5 and 2.5 mg/kg
Model: Male Wistar rats
Methods and source locations

Compound reported in the paper: Varenicline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Animals (S1, S3); Methods > Apparatus and behavioural procedure > Self-administration (S11); Methods > Drugs (S61, S62); Results > Experiment 1: nicotine self-administration (S70, S72)

total number of active nose pokes: total number of active nose pokes; comparator: vehicle — Results > Experiment 1: nicotine self-administration (S72)

Varenicline 0.5, 1.5 and 2.5 mg/kg · Methods > Drugs (S62); Results > Experiment 1: nicotine self-administration (S72)

Ethanol and Water Intake Following Local Microinfusion

Animal study · Male Wistar rats; rats chronically drinking ethanol in the two-bottle choice model (n = 8–12 animals per brain region) [3]

Varenicline or vehicle infusions did not affect water intake (30 min, 4 and 24 h) or ethanol intake (4 and 24 h).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ethanol intake (mL); 4 hethanol intake NAc core-shell border; 2 µg; 4 h: 1.9 ± 0.2 mL[3]

Conditions shared by the study groups

Route
Microinfusion; into the NAc core-shell border
Treatment course
for 4 min; drinking sessions commenced 10 min after infusions; 1 week between treatments
Vehicle
10% potassium phosphate buffer/90% isotonic saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Varenicline 2 µgVehicle; 2.1 ± 0.1 mL1.9 ± 0.2 mL; do not affect water intake (30 min, 4 and 24 h) or ethanol intake (4 and 24 h)[3]
Varenicline 2 µg
Model: Male Wistar rats; rats chronically drinking ethanol in the two-bottle choice model (n = 8–12 animals per brain region)
Methods and source locations

Compound reported in the paper: Varenicline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Drugs and chemicals (S5); Methods > Animals and housing (S8); Methods > Ethanol drinking paradigms (S12); Methods > Surgical procedures (S16); Methods > Microinjection procedures (S27, S28, S29); Results > Microinfusion of varenicline (S58, S59); Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r5, T1.r8)

Ethanol intake (mL); 4 h: Ethanol intake (mL); 4 h; comparator: Vehicle; 2.1 ± 0.1 mL — Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r5, T1.r8)

Varenicline 2 µg · Methods > Microinjection procedures (S27, S28, S29); Results > Microinfusion of varenicline (S59); Table 1 legend (S100); Table 1 (T1.h1, T1.h2, T1.r8)

Varenicline and nicotine omission in Cluster A rats

Animal study · Male Sprague–Dawley rats; n = 29 Cluster A [1]

Male Sprague–Dawley rats in Cluster A received Varenicline at 1 mg/kg free base by intraperitoneal injection. Varenicline pretreatment had no significant effect on the global effect of nicotine omission compared with nicotine omission without Varenicline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Global effect of nicotine omissionReported result it had no significant effect in Cluster A[1]

Conditions shared by the study groups

Route
intraperitoneal (i.p.) injection
Treatment course
30 min before the session began; session 23
Vehicle
sterile 0.9% physiological saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Varenicline 1 mg/kg free basenicotine omission without (NicOm)it had no significant effect in Cluster A[1]
Varenicline 1 mg/kg free base
Model: Male Sprague–Dawley rats; n = 29 Cluster A
Methods and source locations

Compound reported in the paper: Varenicline

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S1); Materials and methods > Nicotine intravenous self-administration (S17); Materials and methods > Nicotine intravenous self-administration > Self-administration standard protocol (S22); Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 1 legend (S157); Fig. 4 legend (S170)

Global effect of nicotine omission: Global effect of nicotine omission; comparator: nicotine omission without (NicOm) — Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155); Fig. 4 legend (S170)

Varenicline 1 mg/kg free base · Materials and methods > Behavioral characterization of the identified clusters (S51, S54, S55); Results > Psychopharmacological features of clusters A and B > Varenicline effect on nicotine seeking in Clusters A and B (S155)

Specifications

Manufacturer Adooq Bioscience
Actions Partial Agonist
CAS Number 249296-44-4
Applications nAChR partial agonist
Formula C13H13N3
Molecular Weight 211.3
Synonyms Chantix
SMILES
C1C2CNCC1C3=CC4=NC=CN=C4C=C23

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Varenicline Research References

  1. [1] Garcia-Rivas V, Fiancette JF, Tostain J, et al. Individual variations in motives for nicotine self-administration in male rats: evidence in support for a precision psychopharmacology. Transl Psychiatry (2024). PMID: 38336930 DOI: 10.1038/s41398-024-02774-6 Source material
  2. [2] Wouda JA, Riga D, De Vries W, et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) (2011). PMID: 21331520 DOI: 10.1007/s00213-011-2213-8 Source material
  3. [3] Feduccia AA, Simms JA, Mill D, et al. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. Br J Pharmacol (2014). PMID: 24628360 DOI: 10.1111/bph.12690 Source material

Added to your cart

View Cart Checkout
Loading...